ReviewFrontiers in microbiology2018
Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects.
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Risk factors forMicrobiology spectrum · 2026Article
- Predictors of 30-day mortality in critically ill patients with bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a five-year retrospective study.BMC infectious diseases · 2025Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coli in recurrent and multi-site infections.Gut pathogens · 2025Article
- Prevalence of Carbapenemase Production Among Klebsiella and Escherichia coli Isolated From Urinary Tract Infections.Cureus · 2024Article
- Review
- Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study.Infection and drug resistance · 2024Article
- In Vitro Activity of New β-Lactamase Inhibitor Combinations againstAntibiotics (Basel, Switzerland) · 2023Article
- [Antimicrobial Resistance and Molecular Characteristics of Carbapenem-resistantJugan geon-gang gwa jilbyeong · 2023Article
- Fecal carriage and genetic characteristics of carbapenem-resistant enterobacterales among adults from four provinces of China.Frontiers in epidemiology · 2023Article
- Phase Contrast Image-Based Rapid Antimicrobial Susceptibility Testing of Bacteria in Liquid Culture Media.Sensors (Basel, Switzerland) · 2022Article
- Infection Sources andAntibiotics (Basel, Switzerland) · 2022Article
- Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-ResistantMicrobiology spectrum · 2022Article
- Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem-NonsusceptiblePathogens (Basel, Switzerland) · 2022Article
- Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Frontiers in cellular and infection microbiology · 2022Review
- A Longitudinal Nine-Year Study of the Molecular Epidemiology of Carbapenemase-ProducingFrontiers in microbiology · 2022Article
- Risk Factors and Clinical Impact of Carbapenem-ResistantInfection and drug resistance · 2022Article
- In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.The Journal of antimicrobial chemotherapy · 2021Article
- Increasing New Delhi metallo-β-lactamase-positive Escherichia coli among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018.Scientific reports · 2021Article
- Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review.Frontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE), a major resistance concern emerging during the last decade because of significantly compromising the efficacy of carbapenem agents, has currently become an important focus of infection control. Many investigations have shown a high association of CRE infections with high case-fatality rates. In Taiwan, a few surveys observed that a significant proportion (29-47%) of the CR-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.